S

Sunnybrook Research Institute | Odette Cancer Centre - Clinical Trials

Research site
(Unclaimed)
Location
2075 Bayview Avenue, Toronto, Ontario, Canada
Site insights

Top conditions

Breast Cancer (13 trials)

Prostatic Cancer (6 trials)

Melanoma (5 trials)

Amyotrophic Lateral Sclerosis (4 trials)

Carcinoma (4 trials)

Top treatments

Pembrolizumab
Palbociclib
Doxorubicin
Enzalutamide
ARV-471
Platinum
PD-0332991
Cyclophosphamide
Abemaciclib
Atezolizumab

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Trials

32 of 81
Status: Active
Trial type: Interventional
Funder type: Industry

Filters
3
A Phase 1 Study to Investigate the Safety and Pharmacokinetics of ABBV-CLS-7262 in Patients With Amyotrophic Lateral Sclerosis

ABBV-CLS-7262 is an investigational drug being researched for the treatment of Amyotrophic Lateral Sclerosis. This is an up to 156-week, 2-part study...

Active, not recruiting
ALS
Amyotrophic Lateral Sclerosis
Drug: Placebo
Drug: ABBV-CLS-7262
Locations recently updated

The purpose of this study is to learn whether adding abemaciclib to abiraterone plus prednisone prolongs the time before prostate cancer gets worse....

Active, not recruiting
Cytochrome P-450
Antineoplastic Agents, Hormonal
Drug: Placebo for Abemaciclib
Drug: Abemaciclib

This is a global Phase III, randomized, placebo-controlled, double-blind study designed to evaluate the efficacy and safety of adjuvant treatment wit...

Enrolling
Muscle-invasive Bladder Cancer
Drug: Atezolizumab
Other: Placebo

This is a phase 3 randomized trial evaluating the anti-tumor activity and safety of avelumab in combination with axitinib and of sunitinib monotherap...

Active, not recruiting
Renal Cell Cancer
Drug: Axitinib (AG-013736)
Drug: Avelumab (MSB0010718C)

This study will evaluate the efficacy, safety and patient-reported outcomes of trastuzumab emtansine plus atezolizumab compared with trastuzumab emta...

Active, not recruiting
Metastatic Breast Cancer
Other: Placebo
Drug: Atezolizumab

The primary objective of the study is to demonstrate superior efficacy of Xevinapant (Debio 1143) vs placebo when added to chemoradiotherapy (CRT) in...

Active, not recruiting
Squamous Cell Carcinoma of the Head and Neck
Drug: Placebo
Drug: Xevinapant (Debio 1143)

This is a multicenter, Phase 2a, open-label, 2-part study to investigate the safety, tolerability, and anti-tumor activity of ZW25 (zanidatamab) in c...

Active, not recruiting
HER2+/HR+ Breast Cancer
Drug: ZW25 (Zanidatamab)
Drug: Palbociclib

A study to learn about a new medicine called ARV-471 (PF-07850327) in people who have advanced metastatic breast cancer.

Enrolling
Advanced Breast Cancer
Drug: Fulvestrant
Drug: ARV-471

The purpose of this clinical trial is to learn the safety and effects of the study medicine (PF-07799544) administered as a single agent and in combi...

Enrolling
Glioma
Melanoma
Drug: PF-07799933
Drug: PF-07799544

The purpose of this study is to compare the efficacy and safety of fixed duration pirtobruitinib (LOXO-305) with VR (Arm A) compared to VR alone (Arm...

Enrolling
Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia
Drug: Venetoclax
Drug: Rituximab

This study is researching an experimental drug called REGN3767, also known as fianlimab (R3767), when combined with another medication called cemipli...

Enrolling
Melanoma
Drug: Pembrolizumab
Drug: Placebo

The goal of this clinical trial is to test alternative dosing of niraparib in patients with newly diagnosed high-grade, advanced stage ovarian cancer...

Enrolling
Stage III Ovarian Cancer
High Grade Ovarian Serous Adenocarcinoma
Drug: Niraparib

The purpose of this study is to evaluate the safety and efficacy of targeted blood brain barrier disruption with Exablate Model 4000 Type 2.0/2.1 in...

Enrolling
Brain Tumor
Device: Exablate
Drug: Doxorubicin

The purpose of this study is to evaluate the safety and efficacy of targeted blood brain barrier disruption with Exablate Model 4000 Type 2.0/2.1 for...

Enrolling
Brain Tumor
Device: Blood Brain Barrier Disruption - Oncology
Drug: Pembrolizumab

The purpose of this study is to evaluate the safety and efficacy of targeted blood brain barrier disruption with Exablate Model 4000 Type 2.0/2.1 for...

Enrolling
Glioblastoma
Glioma
Device: Focused Ultrasound (Exablate Model 4000)

Multi-center, prospective, concurrently controlled, non-randomized, double-blind (patient and assessor). Treatment of large chondral lesions in the k...

Enrolling
Knee Injuries
Cartilage Injury
Device: Microfracture plus placement of Chondro-Gide® ACC
Procedure: Microfracture

This study is researching an experimental drug called REGN3767, also known as fianlimab (R3767), when combined with another medication called REGN281...

Enrolling
Melanoma
Drug: Cemiplimab
Drug: Placebo

The purpose of this study is to determine if enzalutamide given in combination with exemestane is safe and effective in patients with advanced breast...

Active, not recruiting
Breast Cancer
Drug: Enzalutamide
Drug: exemestane

A Phase 2b/3 multicenter, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy, safety and tolerability of MN-...

Enrolling
Amyotrophic Lateral Sclerosis
Drug: placebo
Drug: MN-166

To determine whether Instylla HES has the ability to effectively embolize targeted arterial segments of hypervascular tumors as well as (i.e., is non...

Enrolling
Hypervascular Tumors
Other: TAE or cTACE
Device: Instylla HES

Trial sponsors

Pfizer logo

Pfizer (15 trials)

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems